What it isLong-acting benzodiazepine GABA-A modulator approved for insomnia.
Why this oneLong-lived active metabolites sustain sleep, but this rarely outweighs the next-day burden.
What limits itAccumulation causes prolonged sedation, impaired driving, falls, and confusion, particularly in older adults; dependence limits chronic use.
BOXED WARNING Concomitant opioid use risks profound sedation, respiratory depression, coma, death; risk of abuse, misuse, addiction; dependence and withdrawal reactions.
FDA dosing
Population
Start
Target
Max
Insomnia
Women
15 mg QHS
15 mg QHS
30 mg QHS
Insomnia
Men
15-30 mg QHS
15-30 mg QHS
30 mg QHS
Insomnia
Elderly or debilitated
15 mg QHS
15 mg QHS
15 mg QHS
Renal Undefined
Hepatic Undefined
Instructions
Use lowest effective dose
Taper gradually to discontinue or reduce dose to avoid withdrawal reactions
If withdrawal occurs, pause taper or return to prior dose then decrease more slowly
Cautions
CNS-depressant effects and next-day impairment; caution driving
Sleep-driving and complex behaviors while not fully awake
Severe anaphylactic/anaphylactoid reactions, angioedema
Worsening of depression/suicidal thinking
Neonatal sedation and withdrawal syndrome
Failure to remit after 7-10 days may indicate underlying illness
Adverse reactions
Dizziness
Drowsiness
Light-headedness
Staggering
Ataxia
Falling
Pregnancy Neonates exposed late in pregnancy may experience sedation and/or neonatal withdrawal; observational data do not report clear association with major birth defects.